265 results
Page 2 of 14
8-K
EX-99.1
8i3jknx
3 Nov 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
4:01pm
8-K
EX-99.1
zg0 52barfd2aqylaai
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-99.2
ezdq326 tctus0627s
17 Oct 23
Entry into a Material Definitive Agreement
8:32am
8-K
EX-10.1
jgn4e
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-99.1
d5prjkhdm oojum1
5 Oct 23
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
424B5
642kics
5 Oct 23
Prospectus supplement for primary offering
10:47am
8-K
EX-99.1
q11kx
4 Oct 23
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
8:30am
8-K
EX-99.1
d3gksnua6
3 Oct 23
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8:30am
8-K
EX-99.1
12tjdbshbap4w
31 Aug 23
Kineta to Participate in Upcoming Investor Conferences
9:30am
8-K
EX-99.1
29r 07u3b0dszy
11 Aug 23
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
8zr5an1
11 Aug 23
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-99.1
64c42i
29 Jun 23
Kineta to Receive $5 Million Milestone Payment from Merck
7:01am
8-K
EX-99.1
vyrgpvel7gbmjgai3dq
28 Jun 23
Departure of Directors or Certain Officers
7:00am
424B3
74z3l2p
12 Jun 23
Prospectus supplement
5:01pm
8-K
EX-99.1
mipyol 3s5l9nnx4
9 Jun 23
Submission of Matters to a Vote of Security Holders
9:00am
8-K
EX-99.1
kkic7in93b4uryw8
24 May 23
Regulation FD Disclosure
9:30am
8-K
EX-99.1
5z376u2hb6 6yu0
23 May 23
Kineta to Present at Jefferies Healthcare Conference
9:30am